14
Participants
Start Date
August 27, 2014
Primary Completion Date
March 13, 2015
Study Completion Date
March 13, 2015
ALXN1210
All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.
Placebo
All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.
Clinical Trial Site, Montreal
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY